Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy
- Substances:AnastrozoleCamizestrant+6
Hungary- Participants:18–64 years · 65+ years
- Substances:Anastrozole
- Sponsor:AstraZeneca AB
Rare diseases
Investigational molecules
Locations
Back to Hungary163 clinical trials in Nyiregyhaza, Hungary across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.
Hungary
Hungary
Hungary
Hungary
Hungary
Hungary
Hungary
Hungary
Hungary
Hungary
Hungary
HungaryThe busiest research cities in the country
What the registry says about research in the country
Innovative trials focusing on breast cancer treatments, including studies for triple-negative and HR-positive/HER2-negative variants. Research extends to bladder cancer and lymphoma treatments.
Several studies are evaluating novel drug combinations and comparing their efficacy to standard treatments.
Comprehensive research into heart failure prevention and treatment of cardiovascular disease. Studies include innovative approaches for managing chronic conditions.
Trials are investigating new therapeutic combinations to improve patient outcomes in cardiovascular conditions.
Studies addressing chronic rhinosinusitis and respiratory infections, with particular focus on nasal polyps treatment and viral lung infections.
Research includes both preventive measures and therapeutic interventions for respiratory conditions.
Tell us about your condition – we search every trial in Europe and connect you with the right site.